Cheng Zhe, Kang Yan, Wu Qiu-ge, Dai Ling-ling, Song Yong-na, Xia Jie, Si Ji-ming, Chen Chun-yan
Department of Respiratory and Critical Care Medicine, First Affiliated Hospital, Zhengzhou University, China.
Zhonghua Yi Xue Za Zhi. 2011 Nov 15;91(42):2981-4.
To explore the relationship between the sputum levels of high mobility group protein B1 (HMGB1) and airway inflammation in bronchial asthma and chronic obstructive pulmonary disease (COPD) patients.
A total of 57 patients with persistent asthma [per Global Initiative for Asthma (GINA) guidelines], 30 patients with stable COPD [stratified by Global Initiative for COPD (GOLD) status] and 20 control subjects were recruited. After completing an asthma control questionnaire, spirometry was performed before sputum induction. The ratio of forced expiratory volume in the first second (FEV(1))/predictive value (FEV(1)%Pre) and neutrophil differential count in induced sputum were recorded. The concentrations of HMGB1 in the supernatant of sputum were measured by ELISA (enzyme-linked immunosorbent assay).
The sputum concentrations of HMGB1 in the asthmatics and COPD patients were significantly higher than those of the control subjects [(291 ± 55) and (511 ± 39) vs (61 ± 5) ng/L, all P < 0.01]. And they were significantly negatively correlated with FEV(1)%Pre in all subjects. The levels of HMGB1 in induced sputum of COPD patients were significantly higher than those of asthmatics and healthy controls (P < 0.01). No significant difference existed in the levels of HMGB1 between patients with eosinophilic and noneosinophilic asthma [(290 ± 55) vs (292 ± 54) ng/L, P > 0.05]. The HMGB1 levels with COPD stage II and stage III were significantly higher than those with stage I [(526 ± 29) and (541 ± 29) vs (471 ± 18) ng/L]. The differences of sputum neutrophil percentage were statistically significant in mild, moderate and severe asthma [(27 ± 2)%, (36 ± 4)%, (49 ± 4)%]. And the sputum levels of HMGB1 were significantly higher in the patients with moderate and severe asthma [(312 ± 14) vs (347 ± 11) ng/L]. And the levels of HMGB1 in asthmatic and COPD patients were positively correlated with neutrophil percentage. According to the multivariate analysis, neutrophil percentage and FEV(1)%Pre were independent predictors of sputum HMGB1, but not smoking, age, gender and eosinophilic percentage.
HMGB1 may contribute to airway inflammation through its higher expression in bronchial asthma and COPD patients.
探讨支气管哮喘和慢性阻塞性肺疾病（COPD）患者痰液中高迁移率族蛋白B1（HMGB1）水平与气道炎症之间的关系。
共招募57例持续性哮喘患者[根据全球哮喘防治创议（GINA）指南]、30例稳定期COPD患者[根据慢性阻塞性肺疾病全球倡议（GOLD）分级]和20例对照者。完成哮喘控制问卷后，在诱导痰液前进行肺功能测定。记录第1秒用力呼气容积（FEV(1)）/预测值（FEV(1)%Pre）及诱导痰液中的中性粒细胞分类计数。采用酶联免疫吸附测定（ELISA）法检测痰液上清液中HMGB1的浓度。
哮喘患者和COPD患者痰液中HMGB1浓度显著高于对照者[（291±55）和（511±39）对（61±5）ng/L，P均<0.01]。且在所有受试者中，其与FEV(1)%Pre显著负相关。COPD患者诱导痰液中HMGB1水平显著高于哮喘患者和健康对照者（P<0.01）。嗜酸性粒细胞性哮喘患者与非嗜酸性粒细胞性哮喘患者的HMGB1水平无显著差异[（290±55）对（292±54）ng/L，P>0.05]。COPDⅡ期和Ⅲ期患者的HMGB1水平显著高于Ⅰ期患者[（526±29）和（541±29）对（471±18）ng/L]。轻度、中度和重度哮喘患者痰液中性粒细胞百分比差异有统计学意义[（27±2）%、（36±4）%、（49±4）%]。中度和重度哮喘患者痰液中HMGB1水平显著更高[（312±14）对（347±11）ng/L]。哮喘患者和COPD患者的HMGB1水平与中性粒细胞百分比呈正相关。多因素分析显示，中性粒细胞百分比和FEV(1)%Pre是痰液HMGB1的独立预测因素，而吸烟、年龄、性别和嗜酸性粒细胞百分比不是。
HMGB1可能通过在支气管哮喘和COPD患者中高表达而促进气道炎症。
